Introduksjon
Denne siden gir en grundig analyse av den kjente historikken for insidernes handelsaktiviteter for Adam Dubow. Insidere er ledere, direktører eller betydelige investorer i et selskap. Det er ulovlig for insidere å gjøre handler i deres selskaper basert på spesifikke, ikke-offentlig informasjon. Dette betyr ikke at det er ulovlig for dem å gjøre noen handler i deres egne selskaper. Imidlertid må de rapportere alle handler til SEC via et skjema 4. Til tross for disse begrensningene, antyder akademisk forskning at insidere - generelt sett - har en tendens til å overgå markedet i sine egne selskaper.
Gjennomsnittlig handelslønnsomhet
Den gjennomsnittlige handelslønnsomheten er den gjennomsnittlige avkastningen av alle åpne markedskjøp gjort av insideren de siste tre årene. For å beregne dette, undersøker vi hvert eneste åpne marked, uplanlagte kjøp som er gjort av insideren, men dette inkluderer ikke alle handler som ble markert som en del av en 10b5-1 handelsplan. Vi beregner deretter gjennomsnittlig ytelse av disse handlene over 3, 6 og 12 måneder, gjennomsnittlig hver av disse varighetene for å generere en endelig ytelsesmåling for hver handel. Til slutt,
Dersom lønnsomheten for denne interne handelen er "N/A", har enten den interne personen ikke gjort noen åpen-markeds kjøp de siste tre årene, eller så er handlene for nylig til å beregne en pålitelig prestasjonsmåler.
Oppdateringsfrekvens: Daglig
Selskaper med rapporterte insiderposisjoner
SEC-arkiveringene indikerer at Adam Dubow har rapporterte beholdninger av handler i følgende selskaper:
Verdipapir | Navn | Siste rapporterte høydepunkter |
---|---|---|
US:DAWN / Day One Biopharmaceuticals, Inc. | Gen Counsel & Secretary | 54 858 |
US:BMY / Bristol-Myers Squibb Company | SVP,ChiefCompliance&EthicsOff. | 13 777 |
Hvordan tolke diagrammene
De følgende diagrammene viser aksjens ytelse etter hver åpen markedstransaksjon som ikke var planlagt, utført av Adam Dubow. Ikke-planlagte handler er handler som ikke ble gjort som en del av en 10b5-1 handelsplan. Aksjeytelsen er kartlagt som kumulativ prosentendring i aksjekursen. For eksempel, hvis en innsidehandel ble gjort 1. januar 2019, vil diagrammet vise daglig prosentendring for verdipapiret til dagens dato. Dersom aksjeprisen går fra $10 til $15 i løpet av denne tiden, vil den kumulative prosentendringen i aksjeprisen være 50%. En endring i prisen fra $10 til $20 vil være 100%, og en endring i prisen fra $10 til $5 vil være - 50%.
Til syvende og sist er målet vårt å avgjøre hvor tett insidernes handler korrelerer med overavkastninger (positiv eller negativ) i aksjekursen for å se om insidere timer sine handler for å tjene på intern informasjon. Se for deg en situasjon der en insider gjør dette. I denne situasjonen, forventer vi enten (a) positive avkastninger etter kjøp, eller (b) negative avkastninger etter salg. I tilfelle (a) KJØP-diagrammet ville vise en serie av oppadgående kurver, som indikerer positive avkastninger etter hver kjøpstransaksjon. I tilfelle (b) ville SALG-diagrammet vise en serie av nedadgående kurver, som indikerer negative avkastninger etter hver salgstransaksjon.
Imidlertid er dette alene ikke nok til å dra konklusjoner. Hvis, for eksempel, aksjeprisen for selskapet steg jevnt over mange år uten å følge en syklisk trend, ville vi forventet at alle postkjøpsdiagrammer skal ha en stigende trend. På samme måte vil ikke-sykliske nedganger over mange år resultere i nedadgående trend i post-trade diagrammer. Ingen av disse diagrammene ville antyde aktiviteter som insidertrening.
Den sterkeste indikatoren ville vært en situasjon der aksjekursen var ekstremt syklisk, og det var både positive signaler i KJØPSdiagrammet og negative plot i SALGSdiagrammet. Denne situasjonen ville vært sterkt antydende om en insider som timet handler til sin økonomiske fordel.
Innsidernes handelshistorikk
Tabellen viser den komplette listen over innsidehandler gjort av Adam Dubow som avslørt til Securies Exchange Comission (SEC).
Fildato | Transaksjonsdato | Skjema | Ticker | Verdipapir | Kode | Aksjer | Gjenværende aksjer | Prosent endring |
Aksje pris |
Transaksjons verdi |
Gjenværende verdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-08-19 |
|
4 | DAWN |
Day One Biopharmaceuticals, Inc.
Common Stock |
S - Sale | −4 365 | 54 858 | −7,37 | 6,77 | −29 538 | 371 230 | |
2025-08-19 |
|
4 | DAWN |
Day One Biopharmaceuticals, Inc.
Common Stock |
M - Exercise | 3 687 | 59 223 | 6,64 | ||||
2025-08-19 |
|
4 | DAWN |
Day One Biopharmaceuticals, Inc.
Common Stock |
M - Exercise | 3 687 | 59 223 | 6,64 | ||||
2025-08-19 |
|
4 | DAWN |
Day One Biopharmaceuticals, Inc.
Common Stock |
M - Exercise | 1 750 | 51 849 | 3,49 | ||||
2025-08-19 |
|
4 | DAWN |
Day One Biopharmaceuticals, Inc.
Common Stock |
M - Exercise | 2 963 | 50 099 | 6,29 | ||||
2025-05-19 |
|
4 | DAWN |
Day One Biopharmaceuticals, Inc.
Common Stock |
S - Sale | −4 552 | 47 136 | −8,81 | 6,26 | −28 486 | 294 972 | |
2025-05-19 |
|
4 | DAWN |
Day One Biopharmaceuticals, Inc.
Common Stock |
M - Exercise | 3 687 | 51 688 | 7,68 | ||||
2025-05-19 |
|
4 | DAWN |
Day One Biopharmaceuticals, Inc.
Common Stock |
M - Exercise | 3 687 | 51 688 | 7,68 | ||||
2025-05-19 |
|
4 | DAWN |
Day One Biopharmaceuticals, Inc.
Common Stock |
M - Exercise | 1 750 | 44 314 | 4,11 | ||||
2025-05-19 |
|
4 | DAWN |
Day One Biopharmaceuticals, Inc.
Common Stock |
M - Exercise | 2 962 | 42 564 | 7,48 | ||||
2025-02-21 |
|
4 | DAWN |
Day One Biopharmaceuticals, Inc.
Common Stock |
S - Sale | −4 646 | 39 602 | −10,50 | 11,96 | −55 580 | 473 759 | |
2025-02-21 |
|
4 | DAWN |
Day One Biopharmaceuticals, Inc.
Common Stock |
M - Exercise | 3 687 | 44 248 | 9,09 | ||||
2025-02-21 |
|
4 | DAWN |
Day One Biopharmaceuticals, Inc.
Common Stock |
M - Exercise | 3 687 | 44 248 | 9,09 | ||||
2025-02-21 |
|
4 | DAWN |
Day One Biopharmaceuticals, Inc.
Common Stock |
M - Exercise | 1 750 | 36 874 | 4,98 | ||||
2025-02-21 |
|
4 | DAWN |
Day One Biopharmaceuticals, Inc.
Common Stock |
M - Exercise | 2 962 | 35 124 | 9,21 | ||||
2024-11-19 |
|
4 | DAWN |
Day One Biopharmaceuticals, Inc.
Common Stock |
S - Sale | −3 165 | 32 162 | −8,96 | 13,21 | −41 810 | 424 866 | |
2024-11-19 |
|
4 | DAWN |
Day One Biopharmaceuticals, Inc.
Common Stock |
M - Exercise | 3 687 | 35 327 | 11,65 | ||||
2024-11-19 |
|
4 | DAWN |
Day One Biopharmaceuticals, Inc.
Common Stock |
M - Exercise | 1 750 | 31 640 | 5,85 | ||||
2024-11-19 |
|
4 | DAWN |
Day One Biopharmaceuticals, Inc.
Common Stock |
M - Exercise | 2 962 | 29 890 | 11,00 | ||||
2024-08-19 |
|
4 | DAWN |
Day One Biopharmaceuticals, Inc.
Common Stock |
S - Sale | −3 202 | 26 928 | −10,63 | 14,00 | −44 825 | 376 968 | |
2024-08-19 |
|
4 | DAWN |
Day One Biopharmaceuticals, Inc.
Common Stock |
M - Exercise | 3 687 | 30 130 | 13,94 | ||||
2024-08-19 |
|
4 | DAWN |
Day One Biopharmaceuticals, Inc.
Common Stock |
M - Exercise | 1 750 | 26 443 | 7,09 | ||||
2024-08-19 |
|
4 | DAWN |
Day One Biopharmaceuticals, Inc.
Common Stock |
M - Exercise | 2 962 | 24 693 | 13,63 | ||||
2024-05-17 |
|
4 | DAWN |
Day One Biopharmaceuticals, Inc.
Common Stock |
S - Sale | −3 253 | 21 731 | −13,02 | 16,08 | −52 304 | 349 406 | |
2024-05-17 |
|
4 | DAWN |
Day One Biopharmaceuticals, Inc.
Common Stock |
M - Exercise | 3 687 | 24 984 | 17,31 | ||||
2024-05-17 |
|
4 | DAWN |
Day One Biopharmaceuticals, Inc.
Common Stock |
M - Exercise | 1 750 | 21 297 | 8,95 | ||||
2024-05-17 |
|
4 | DAWN |
Day One Biopharmaceuticals, Inc.
Common Stock |
M - Exercise | 2 962 | 19 547 | 17,86 | ||||
2024-02-20 |
|
4 | DAWN |
Day One Biopharmaceuticals, Inc.
Common Stock |
S - Sale | −3 242 | 16 585 | −16,35 | 15,25 | −49 434 | 252 890 | |
2024-02-20 |
|
4 | DAWN |
Day One Biopharmaceuticals, Inc.
Common Stock |
M - Exercise | 3 687 | 19 827 | 22,84 | ||||
2024-02-20 |
|
4 | DAWN |
Day One Biopharmaceuticals, Inc.
Common Stock |
M - Exercise | 1 750 | 16 140 | 12,16 | ||||
2024-02-20 |
|
4 | DAWN |
Day One Biopharmaceuticals, Inc.
Common Stock |
M - Exercise | 2 962 | 14 390 | 25,92 | ||||
2023-11-17 |
|
4 | DAWN |
Day One Biopharmaceuticals, Inc.
Common Stock |
S - Sale | −5 313 | 11 428 | −31,74 | 11,69 | −62 109 | 133 593 | |
2023-11-17 |
|
4 | DAWN |
Day One Biopharmaceuticals, Inc.
Common Stock |
M - Exercise | 1 750 | 16 741 | 11,67 | ||||
2023-11-17 |
|
4 | DAWN |
Day One Biopharmaceuticals, Inc.
Common Stock |
M - Exercise | 11 850 | 14 991 | 377,27 | ||||
2023-11-16 | 3 | DAWN |
Day One Biopharmaceuticals, Inc.
Common Stock |
3 141 | ||||||||
2021-08-03 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −2 466 | 13 777 | −15,18 | 67,90 | −167 441 | 935 469 | |
2021-05-07 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −3 119 | 16 243 | −16,11 | 64,21 | −200 271 | 1 042 973 | |
2021-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Performance Shares |
A - Award | 5 972 | 5 972 | |||||
2021-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Performance Shares |
M - Exercise | −2 495 | 0 | −100,00 | ||||
2021-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Market Share Units |
A - Award | 3 981 | 3 981 | |||||
2021-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Market Share Units |
M - Exercise | −980 | 2 943 | −24,98 | ||||
2021-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Market Share Units |
M - Exercise | −1 062 | 2 124 | −33,33 | ||||
2021-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Market Share Units |
M - Exercise | −415 | 418 | −49,82 | ||||
2021-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Market Share Units |
M - Exercise | −452 | 0 | −100,00 | ||||
2021-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −935 | 19 362 | −4,61 | 60,93 | −56 970 | 1 179 736 | |
2021-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
J - Other | 486 | 20 297 | 2,45 | ||||
2021-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 2 495 | 19 811 | 14,41 | ||||
2021-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −313 | 17 316 | −1,78 | 60,93 | −19 071 | 1 055 073 | |
2021-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
J - Other | 18 | 17 629 | 0,10 | ||||
2021-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 980 | 17 611 | 5,89 | ||||
2021-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −391 | 16 631 | −2,30 | 60,93 | −23 824 | 1 013 336 | |
2021-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
J - Other | 184 | 17 022 | 1,09 | ||||
2021-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 1 062 | 16 838 | 6,73 | ||||
2021-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −119 | 15 776 | −0,75 | 60,93 | −7 251 | 961 241 | |
2021-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
J - Other | −36 | 15 895 | −0,23 | ||||
2021-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 415 | 15 931 | 2,67 | ||||
2021-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −152 | 15 516 | −0,97 | 60,93 | −9 261 | 945 399 | |
2021-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
J - Other | 30 | 15 668 | 0,19 | ||||
2021-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 452 | 15 638 | 2,98 | ||||
2020-11-25 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −900 | 15 186 | −5,59 | 63,39 | −57 051 | 962 650 | |
2020-05-26 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −3 200 | 16 086 | −16,59 | 61,01 | −195 232 | 981 416 | |
2020-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Performance Shares |
A - Award | 5 885 | 5 885 | |||||
2020-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Performance Shares |
M - Exercise | −2 707 | 0 | −100,00 | ||||
2020-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Market Share Units |
A - Award | 3 923 | 3 923 | |||||
2020-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Market Share Units |
M - Exercise | −1 062 | 3 186 | −25,00 | ||||
2020-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Market Share Units |
M - Exercise | −415 | 833 | −33,25 | ||||
2020-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Market Share Units |
M - Exercise | −451 | 452 | −49,94 | ||||
2020-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Market Share Units |
M - Exercise | −372 | 0 | −100,00 | ||||
2020-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −1 077 | 19 286 | −5,29 | 57,93 | −62 391 | 1 117 247 | |
2020-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
J - Other | 272 | 20 363 | 1,35 | ||||
2020-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 2 707 | 20 091 | 15,57 | ||||
2020-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −470 | 17 384 | −2,63 | 57,93 | −27 227 | 1 007 064 | |
2020-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
J - Other | 238 | 17 854 | 1,35 | ||||
2020-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 1 062 | 17 616 | 6,42 | ||||
2020-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −143 | 16 554 | −0,86 | 57,93 | −8 284 | 958 982 | |
2020-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
J - Other | −20 | 16 697 | −0,12 | ||||
2020-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 415 | 16 717 | 2,55 | ||||
2020-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −182 | 16 302 | −1,10 | 57,93 | −10 543 | 944 384 | |
2020-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
J - Other | 51 | 16 484 | 0,31 | ||||
2020-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 451 | 16 433 | 2,82 | ||||
2020-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −133 | 15 982 | −0,83 | 57,93 | −7 705 | 925 846 | |
2020-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
J - Other | −6 | 16 115 | −0,04 | ||||
2020-03-12 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 372 | 16 121 | 2,36 | ||||
2019-12-09 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −1 740 | 15 749 | −9,95 | 58,81 | −102 329 | 926 208 | |
2019-03-13 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Performance Shares |
A - Award | 6 372 | 6 372 | |||||
2019-03-13 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Performance Shares |
M - Exercise | −2 196 | 0 | −100,00 | ||||
2019-03-13 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Market Share Units |
A - Award | 4 248 | 4 248 | |||||
2019-03-13 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Market Share Units |
M - Exercise | −415 | 1 248 | −24,95 | ||||
2019-03-13 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Market Share Units |
M - Exercise | −451 | 903 | −33,31 | ||||
2019-03-13 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Market Share Units |
M - Exercise | −369 | 372 | −49,80 | ||||
2019-03-13 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Market Share Units |
M - Exercise | −304 | 0 | −100,00 | ||||
2019-03-13 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −751 | 17 489 | −4,12 | 51,39 | −38 594 | 898 768 | |
2019-03-13 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 2 196 | 18 240 | 13,69 | ||||
2019-03-13 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −109 | 16 044 | −0,67 | 51,39 | −5 602 | 824 509 | |
2019-03-13 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
J - Other | −98 | 16 153 | −0,60 | ||||
2019-03-13 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 415 | 16 251 | 2,62 | ||||
2019-03-13 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −138 | 15 836 | −0,86 | 51,39 | −7 092 | 813 820 | |
2019-03-13 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
J - Other | −49 | 15 974 | −0,31 | ||||
2019-03-13 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 451 | 16 023 | 2,90 | ||||
2019-03-13 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −100 | 15 572 | −0,64 | 51,39 | −5 139 | 800 253 | |
2019-03-13 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
J - Other | −78 | 15 672 | −0,50 | ||||
2019-03-13 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 369 | 15 750 | 2,40 | ||||
2019-03-13 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −84 | 15 381 | −0,54 | 51,39 | −4 317 | 790 437 | |
2019-03-13 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
J - Other | −61 | 15 465 | −0,39 | ||||
2019-03-13 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 304 | 15 526 | 2,00 | ||||
2018-09-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Restricted Stock Units |
M - Exercise | −797 | 0 | −100,00 | ||||
2018-09-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −273 | 15 222 | −1,76 | 60,55 | −16 530 | 921 701 | |
2018-09-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 797 | 15 495 | 5,42 | ||||
2018-06-22 | 3 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
30 283 | ||||||||
2018-06-22 | 3 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
16 472 | ||||||||
2018-06-22 | 3 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
30 283 | ||||||||
2018-06-22 | 3 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
16 472 | ||||||||
2018-06-22 | 3 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
30 283 | ||||||||
2018-06-22 | 3 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
16 472 |